ImmunoVaccine Inc. (TSE:IMV) insider Pierre Labbé acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was purchased at an average cost of C$1.22 per share, with a total value of C$30,500.00.
Pierre Labbé also recently made the following trade(s):
- On Friday, July 28th, Pierre Labbé acquired 26,825 shares of ImmunoVaccine stock. The stock was purchased at an average cost of C$1.22 per share, with a total value of C$32,726.50.
ImmunoVaccine Inc. (IMV) traded down 3.28% during trading on Monday, reaching $1.18. 79,624 shares of the company were exchanged. ImmunoVaccine Inc. has a 52-week low of $0.51 and a 52-week high of $1.70. The firm has a 50-day moving average of $1.21 and a 200-day moving average of $1.18. The firm’s market cap is $141.44 million.
TRADEMARK VIOLATION NOTICE: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/07/31/immunovaccine-inc-tseimv-insider-purchases-c30500-00-in-stock-updated.html.
About ImmunoVaccine
Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company’s DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
Receive News & Ratings for ImmunoVaccine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
